Oxcarbazepine in the maintenance treatment of bipolar disorder

Vasudev, Akshya; Macritchie, Karine; Watson, Stuart; Geddes, John; Young, Allan H.

doi:10.1002/14651858.cd005171.pub2

Cited by 29 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to current knowledge, lamotrigine is the most effective mood stabilizer in preventing bipolar depression relapse [8,9]. Carbamazepine and its chemical derivative, oxcarbazepine, are also used in clinical practice, although their use is supported by not as strong data from controlled clinical trials [10,11]. With respect to antipsychotics, their efficacy as long-term mood stabilizers is being gradually established; however, the strongest data on atypical antipsychotics come from so-called enriched trials [12].…”

Section: Discussion the Identification Of Genetic Factors Associatedmentioning

confidence: 99%

Genetics of Lithium Response in Bipolar Disorder

2018

View full text Add to dashboard Cite

show abstract

Section: Discussion the Identification Of Genetic Factors Associatedmentioning

confidence: 99%

Genetics of Lithium Response in Bipolar Disorder

2018

View full text Add to dashboard Cite

show abstract

“…While a small RCT suggests a lack of efficacy for flupenthixol as maintenance treatment, larger studies are needed before definite conclusions can be drawn (level 3 negative) 393. Likewise, oxcarbazepine adjunctive therapy requires further evaluation (level 4) 394, 395, 396. No recommendation is made for topiramate as there is an absence of controlled data supporting its efficacy in maintenance (level 4 negative), and a lack of efficacy in acute mania381; however, its use may be indicated as it has efficacy for many syndromes that are often comorbid with BD (Section 7).…”

Section: Maintenance Therapy For Bipolar Disordermentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…A second one concluded that the data for oxcarbazepine are of very low quality not allowing firm conclusions (Vasudev et al, 2008). A fair number of meta-analyses focused on lithium.…”

Section: Efficacy Datamentioning

confidence: 99%

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Fountoulakis

Yatham

Grunze

et al. 2016

IJNPPY

View full text Add to dashboard Cite

Background:The current paper includes a systematic search of the literature, a detailed presentation of the results, and a grading of treatment options in terms of efficacy and tolerability/safety.Material and Methods:The PRISMA method was used in the literature search with the combination of the words ‘bipolar,’ ‘manic,’ ‘mania,’ ‘manic depression,’ and ‘manic depressive’ with ‘randomized,’ and ‘algorithms’ with ‘mania,’ ‘manic,’ ‘bipolar,’ ‘manic-depressive,’ or ‘manic depression.’ Relevant web pages and review articles were also reviewed.Results:The current report is based on the analysis of 57 guideline papers and 531 published papers related to RCTs, reviews, posthoc, or meta-analysis papers to March 25, 2016. The specific treatment options for acute mania, mixed episodes, acute bipolar depression, maintenance phase, psychotic and mixed features, anxiety, and rapid cycling were evaluated with regards to efficacy. Existing treatment guidelines were also reviewed. Finally, Tables reflecting efficacy and recommendation levels were created that led to the development of a precise algorithm that still has to prove its feasibility in everyday clinical practice.Conclusions:A systematic literature search was conducted on the pharmacological treatment of bipolar disorder to identify all relevant random controlled trials pertaining to all aspects of bipolar disorder and graded the data according to a predetermined method to develop a precise treatment algorithm for management of various phases of bipolar disorder. It is important to note that the some of the recommendations in the treatment algorithm were based on the secondary outcome data from posthoc analyses.

show abstract

Oxcarbazepine in the maintenance treatment of bipolar disorder

Abstract: Goodwin 1994 Goodwin GM. Recurrence of mania a er lithium withdrawal. Implications for the use of lithium in the treatment of bipolar a ective disorder.

Cited by 29 publications

References 24 publications

Genetics of Lithium Response in Bipolar Disorder

Genetics of Lithium Response in Bipolar Disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Contact Info

Product

Resources

About